Breaking News, Collaborations & Alliances

Takeda Cambridge, Dimerix In Second GPCR Pact

Dimerix Bioscience Pty Ltd. has entered into a second research program with Takeda Cambridge Ltd., a UK based subsidiary of Takeda Pharmaceutical Co.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dimerix Bioscience Pty Ltd. has entered into a second research program with Takeda Cambridge Ltd., a UK based subsidiary of Takeda Pharmaceutical Co. This new program is in addition to the companies’ April 2010 research collaboration. Dimerix is a preclinical stage company developing a pipeline of lead products with highly specific activity and reduced risk of off-target effects. Under the new agreement, Dimerix will continue to use its GPCR-HIT platform and G Protein-Coupled Receptors (GPCR...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters